Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection

Author:

Kim Kwang Su1ORCID,Iwanami Shoya1ORCID,Oda Takafumi2,Fujita Yasuhisa1,Kuba Keiji3ORCID,Miyazaki Taiga4,Ejima Keisuke5ORCID,Iwami Shingo16789ORCID

Affiliation:

1. Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan

2. Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan

3. Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine, Akita, Japan

4. Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

5. Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA

6. Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan

7. Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan

8. NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan

9. Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan

Abstract

The duration of viral shedding is determined by a balance between de novo infection and removal of infected cells. That is, if infection is completely blocked with antiviral drugs (100% inhibition), the duration of viral shedding is minimal and is determined by the length of virus production. However, some mathematical models predict that if infected individuals are treated with antiviral drugs with efficacy below 100%, viral shedding may last longer than without treatment because further de novo infections are driven by entry of the virus into partially protected, uninfected cells at a slower rate. Using a simple mathematical model, we quantified SARS-CoV-2 infection dynamics in non-human primates and characterized the kinetics of viral shedding. We counterintuitively found that treatments initiated early, such as 0.5 d after virus inoculation, with intermediate to relatively high efficacy (30–70% inhibition of virus replication) yield a prolonged duration of viral shedding (by about 6.0 d) compared with no treatment.

Funder

Basic Science Research Program through the National Research Foundation of Korea

Grants-in-Aid for JSPS Research Fellow

Scientific Research (KAKENHI) B

Scientific Research in Innovative Areas

AMED CREST

AMED Japan Program for Infectious Diseases Research and Infrastructure

AMED Research Program on HIV/AIDS

AMED Research Program on Emerging and Re-Emerging Infectious Diseases

AMED Program for Basic and Clinical Research on Hepatitis

AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B

JST MIRAI

Moonshot R&D

Mitsui Life Social Welfare Foundation

Shin-Nihon of Advanced Medical Research

Suzuken Memorial Foundation

Life Science Foundation of Japan

SECOM Science and Technology Foundation

The Japan Prize Foundation

Daiwa Securities Health Foundation

Publisher

Life Science Alliance, LLC

Subject

Health, Toxicology and Mutagenesis,Plant Science,Biochemistry, Genetics and Molecular Biology (miscellaneous),Ecology

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3